As found in a one-arm phase II trial, Infliximab administration reduced the pathological inflammatory cytokine levels among critical and severe COVID-19 inpatients (NCT04425538).64,65 Adalimumab, a recombinant fully-humanized anti-TNF-α McAb IgG, is used in combination with dexamethasone and remdesivir to treat severe COVID-19 cases. This evidence concerns the gene TNF and COVID-19.